Tumor Regression Grade As Predictor of Adjuvant Therapy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tumor Regression Grade As Predictor of Adjuvant Therapy — Stella

Recruiting

Back to Esophageal Squamous Cell Carcinoma (ESCC) trials

Trial locations(1 site)

China

Fujian Medical University Union Hospital, Fuzhou, Fujian

Key details

Sponsor

Fujian Medical University Union Hospital

Collaborators

The First Affiliated Hospital of Xiamen University, Quanzhou First Hospital

Enrollment target

~400 participants

Started

October 2024

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov